Some features may not work as expected in this browser. For the full NewsNow experience, please consider updating your browser or trying a different device. Some features may not work as expected.
Please consider updating your browser or device.

You’re on our free ad-supported tier. Upgrade to NewsNow Essentials for just £4/m now! Your favourite news platform, faster, slicker and ad free.You’re on our free tier. Get NewsNow Essentials at just £4/m now!. Faster, slicker and ad free.You’re on our free tier. Go ad free for just £4/m now!

Home
Hot Topics
US
Politics
World
Sports
Business
Crypto
Entertainment
Lifestyle
AI
Tech
Science

"EGFR"
Topics

Advertisement

Advertisement

"EGFR"

Showing articles that match "EGFR" in the headline

Earlier Today

Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III Nsclc: results of phase III advance trial and real-world validation Nature.com 00:21

Friday

Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer China Money Network 21:40 Fri, 18 Sep

Thursday

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate PR Newswire (Press Release) 07:38 Thu, 17 Sep

Advertisement

Advertisement

Wednesday

REZILIENT3: Adding Zipalertinib to Chemo Improves PFS in EGFR Exon20ins+ NSCLC Oncology Nurse Advisor 14:24 Wed, 16 Sep

Amivantamab Plus Chemo Bests Chemo Alone in Advanced EGFR Ex20ins NSCLC Oncology Nurse Advisor 14:14 Wed, 16 Sep

[Interview] Nelmastobart could pair with osimertinib after clean EGFR safety: STCUBE PHARMACEUTICALS CEO Korea Biomedical Review 09:54 Wed, 16 Sep

Tuesday

Johnson & Johnson (JNJ) Reports Lower Side Effects In Advanced EGFR Lung Cancer Simply Wall St 17:29 Tue, 15 Sep

BlossomHill's Bh-30643 Shows 45% Response In EGFR C797S Nsclc; Stock Up RTT News 14:05 Tue, 15 Sep

Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency Nature.com 13:22 Tue, 15 Sep

BlossomHill To Present Updated Solara Data On Bh-30643 In EGFR-Mutant Lung Cancer Today; Stock Up RTT News 11:22 Tue, 15 Sep

WCLC 2026: Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain... ecancer 10:48 Tue, 15 Sep

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases News-Medical.Net 09:03 Tue, 15 Sep

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations News-Medical.Net 08:12 Tue, 15 Sep

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC News-Medical.Net 06:00 Tue, 15 Sep

Advertisement

In the last month

J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC Clinical Trials Arena 16:47 Mon, 14 Sep

Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive Nsclc PR Newswire (Press Release) 16:32 Mon, 14 Sep

Whitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type Nsclc RTT News 16:22 Mon, 14 Sep

Eight-Year Adaura Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated Nsclc PR Newswire (Press Release) 14:25 Mon, 14 Sep

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer PMLiVE 13:01 Mon, 14 Sep

In the Papillon Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced Nsclc PR Newswire (Press Release) 12:17 Mon, 14 Sep

WCLC 2026: Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon... ecancer 12:15 Mon, 14 Sep

AstraZeneca's Tagrisso Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer RTT News 10:35 Mon, 14 Sep

Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer PharmaTimes 10:31 Mon, 14 Sep

J&J's Rybrevant Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion Nsclc Survival RTT News 09:24 Mon, 14 Sep

β3GnT2-mediated N-glycosylation of EGFR and Ldlr drives glioblastoma progression and can be targeted by AST-1306 Nature.com 06:09 Mon, 14 Sep

Tagrisso demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial AstraZeneca (Press Release) 02:56 Mon, 14 Sep

Johnson & Johnson's Rybrevant® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer PR Newswire (Press Release) 02:53 Mon, 14 Sep

Tagrisso® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in Adaura Phase III trial Business Wire (Press Release) 02:52 Mon, 14 Sep

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at Wclc 2026 PR Newswire (Press Release) 02:32 Mon, 14 Sep

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Business Wire (Press Release) 00:19 Mon, 14 Sep

SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at Wclc Congress 2026 PR Newswire (Press Release) 10:17 Sat, 12 Sep

Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of Avzo-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th Eortc-NCI-Aacr Symposium Business Wire (Press Release) 14:10 Thu, 10 Sep

From next-gen EGFR drugs to AI, Korean firms gear up for WCLC Seoul Korea Biomedical Review 05:45 Wed, 09 Sep

Hutchison China MediTech Announces Licensing Agreement with GlaxoSmithKline for Kras-EGFR Antibody-Drug Conjugate China Money Network 19:28 Thu, 03 Sep

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy® (sunvozertinib) for lung cancer Business Wire (Press Release) 12:02 Tue, 01 Sep

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer AstraZeneca (Press Release) 07:16 Tue, 01 Sep

Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer AstraZeneca (Press Release) 07:06 Tue, 01 Sep

Three-year adjuvant treatment of icotinib in stage II-Iiia EGFR-mutated lung adenocarcinoma (Icwip): a randomized, double-blind, placebo-controlled phase 3 trial Nature.com 00:37 Fri, 28 Aug

Advertisement

Advertisement

News Now

Our Sites

News Now Nigeria

News Now România

News Now Italia

News Now Canada

News Now Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Hot Topics Hot Topics
US US
Politics Politics
World World
Sports Sports
Business Business
Cryptocurrencies
Entertainment
Lifestyle Lifestyle
AI AI
Tech Tech
Science Science